Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1
148
about 7.1 years
18+
1 site in CA
What this study is about
This trial is testing a treatment called CD22CART for adults with relapsed or refractory B cell lymphomas. The treatment involves infusing autologous CAR T cells after lymphodepleting chemotherapy. Participants will be followed to see how long they live, if the cancer comes back, and how long their response lasts.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CD22CART Infusion
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
infusion
Primary: Determine the overall response rate (ORR) in adults with follicular lymphoma (FL) and mantle cell lymphoma (MCL), Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)
Secondary: Assess the response rate in adults with relapsed/refractory Hairy cell leukemia (HCL), Lymphoplasmacytic lymphoma (Waldenstrom macroglobulemia) (WM), Burkitt lymphoma (BL), and Marginal Zone lymphoma (MZL)., Evaluate Duration of Response (DOR), Evaluate Overall Survival (OS), Evaluate Progression Free Survival (PFS)
Oncology